Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.
- Revenue in GBP (TTM)0.00
- Net income in GBP-4.26m
- Incorporated2004
- Employees5.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701
- Websitehttps://sareum.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Saniona AB | 1.54m | -6.20m | 30.41m | 23.00 | -- | 14.98 | -- | 19.71 | -1.09 | -1.09 | 0.2629 | 0.2451 | 0.1726 | -- | 5.63 | 900,521.80 | -69.41 | -59.16 | -127.89 | -70.15 | -136.88 | -970.05 | -402.20 | -1,483.55 | -- | -3.85 | 0.71 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
Xbrane Biopharma AB | 14.22m | -26.91m | 30.76m | 75.00 | -- | 1.05 | -- | 2.16 | -1.33 | -1.58 | 0.6978 | 0.2577 | 0.2465 | 1.34 | 332.12 | 2,053,430.00 | -46.63 | -40.98 | -78.01 | -67.24 | 15.43 | -- | -189.18 | -364.40 | 1.43 | -31.13 | 0.3693 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
Mendus AB (publ) | 0.00 | -7.97m | 31.13m | 28.00 | -- | 0.5329 | -- | -- | -1.59 | -1.59 | 0.00 | 15.57 | 0.00 | -- | -- | 0.00 | -16.09 | -18.84 | -17.35 | -20.21 | -- | -- | -- | -28,474.53 | -- | -150.86 | 0.0348 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
genOway SA | 16.96m | 1.33m | 32.33m | 133.00 | 23.13 | 2.20 | 9.52 | 1.91 | 0.1782 | 0.1782 | 2.28 | 1.88 | 0.619 | 0.773 | 3.10 | 150,724.70 | 4.84 | 0.2166 | 6.64 | 0.3048 | 95.82 | 94.82 | 7.82 | 0.4177 | 1.95 | 28.11 | 0.3047 | -- | 17.55 | 13.16 | 101.55 | 22.35 | -- | -- |
Fermentalg SA | 3.43m | -11.97m | 32.48m | 62.00 | -- | 0.7385 | -- | 9.46 | -0.3176 | -0.3176 | 0.0917 | 0.6033 | 0.0753 | 0.533 | 3.35 | 65,451.61 | -24.63 | -21.94 | -26.79 | -24.71 | 13.21 | 14.73 | -327.08 | -248.95 | 3.53 | -60.94 | 0.3323 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
Lytix Biopharma AS | 294.91k | -6.49m | 32.92m | 10.00 | -- | 7.12 | -- | 111.63 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.0368 | -- | 0.4091 | 399,100.00 | -80.96 | -56.91 | -94.07 | -65.83 | -- | -- | -2,202.36 | -771.78 | -- | -- | 0.0095 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
Bergenbio ASA | 38.50k | -11.42m | 33.10m | 16.00 | -- | 330.18 | -- | 859.77 | -0.1849 | -0.1849 | 0.0003 | 0.0347 | 0.0047 | -- | 0.0485 | 20,840.00 | -139.81 | -66.15 | -275.19 | -78.74 | -- | -- | -29,658.54 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
Incanthera PLC | 0.00 | -1.48m | 33.25m | 8.00 | -- | -- | -- | -- | -0.0192 | -0.0192 | 0.00 | -0.0086 | 0.00 | -- | -- | 0.00 | -373.20 | -101.74 | -- | -132.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -36.11 | -- | -- | -- |
Abionyx Pharma SA | 3.93m | -2.98m | 33.67m | 61.00 | -- | 4.98 | -- | 8.58 | -0.121 | -0.121 | 0.1581 | 0.246 | 0.3027 | 21.86 | 4.20 | 76,694.22 | -22.95 | -18.82 | -32.52 | -28.87 | 13.32 | 14.32 | -75.82 | -128.54 | 1.70 | -- | 0.2997 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
Sequana Medical NV | 602.54k | -27.55m | 33.90m | 62.00 | -- | -- | -- | 56.27 | -1.22 | -1.22 | 0.0266 | -0.6905 | 0.0394 | 1.99 | 9.08 | 11,486.61 | -180.28 | -170.42 | -4,305.25 | -660.97 | -586.32 | -255.63 | -4,572.45 | -3,072.27 | 0.2055 | -8.92 | -- | -- | -22.82 | -7.10 | -5.85 | -- | 79.05 | -- |
Novacyt SA | 7.87m | -25.30m | 34.77m | 222.00 | -- | 0.324 | -- | 4.42 | -0.4234 | -0.4247 | 0.1317 | 1.80 | 0.0528 | 1.33 | 0.2622 | 41,907.38 | -16.96 | 17.69 | -20.71 | 23.82 | 43.21 | 62.82 | -321.40 | 23.87 | 4.98 | -79.02 | 0.0036 | 0.00 | -77.28 | 13.49 | -269.46 | -- | -13.46 | -- |
Hamlet BioPharma AB | 0.00 | -2.49m | 35.21m | 7.00 | -- | 8.17 | -- | -- | -0.2326 | -0.2326 | 0.00 | 0.453 | 0.00 | -- | -- | -- | -63.45 | -83.52 | -69.09 | -107.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
Arecor Therapeutics PLC | 4.57m | -8.55m | 35.99m | 50.00 | -- | 3.78 | -- | 7.87 | -0.2793 | -0.2793 | 0.1493 | 0.3111 | 0.2462 | -- | 1.33 | 91,460.00 | -46.06 | -- | -60.53 | -- | -- | -- | -187.05 | -- | 2.02 | -- | 0.0343 | -- | 90.30 | -- | 7.62 | -- | -- | -- |
Sareum Holdings Plc | 0.00 | -4.26m | 36.16m | 5.00 | -- | 56.45 | -- | -- | -0.0614 | -0.0614 | 0.00 | 0.0059 | 0.00 | -- | -- | 0.00 | -160.20 | -71.41 | -195.05 | -81.48 | -- | -- | -- | -19,709.24 | -- | -6.61 | 0.00 | -- | -- | -- | -46.96 | -- | -- | -- |
Initiator Pharma A/S | 0.00 | -2.56m | 37.19m | 3.00 | -- | 14.67 | -- | -- | -0.6301 | -0.6301 | 0.00 | 0.643 | 0.00 | -- | -- | 0.00 | -70.60 | -68.27 | -73.77 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Oncopeptides AB | 2.92m | -18.31m | 39.84m | 62.00 | -- | -- | -- | 13.66 | -1.93 | -1.93 | 0.3085 | -0.0664 | 0.1517 | -0.2669 | 0.8075 | 687,157.90 | -95.16 | -141.28 | -135.11 | -200.49 | 102.05 | -- | -627.53 | -2,689.06 | 2.33 | -- | 1.06 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 2024 | 4.57m | 4.23% |
HSBC Global Asset Management (UK) Ltd.as of 01 Apr 2024 | 3.29m | 3.04% |
Jarvis Investment Management Ltd.as of 01 Apr 2024 | 1.20m | 1.11% |
IG Markets Ltd.as of 01 Apr 2024 | 420.00k | 0.39% |
Rowan Dartington & Co. Ltd. (Broker)as of 01 Apr 2024 | 172.00k | 0.16% |
Evelyn Partners Investment Management Services Ltd.as of 01 Apr 2024 | 117.00k | 0.11% |
KW Investment Management Ltd.as of 01 Apr 2024 | 108.00k | 0.10% |
iDealing.com Ltd.as of 01 Apr 2024 | 92.00k | 0.09% |
Eurizon Capital SGR SpAas of 01 Apr 2024 | 91.00k | 0.08% |
J. M. Finn & Co. Ltd.as of 01 Apr 2024 | 89.00k | 0.08% |